Skip to main content
Premium Trial:

Request an Annual Quote

Genetimes Distributing NanoInk Products in China

NEW YORK (GenomeWeb News) – NanoInk today announced a non-exclusive deal with Genetimes Technology for the distribution of NanoInk's products in China.

Under the terms of the deal, Genetimes will distribute the Skokie, Ill.-based company's desktop nanofabrication equipment, including the NLP 2000 System and DPN 5000 System. Further details of the deal were not disclosed.

According to Oliver Yeh, general manager of NanoInk's NanoFabrication Systems Division, Asia-Pacific region, Genetimes has offices in 12 cities as well as strong relationships with NanoInk's target customers, making it "the ideal partner for driving sales of NanoInk's unique nanofabrication platforms for use in life science and bioengineering applications."

Genetimes is based in Shanghai and provides products and services for life science research, including next-generation sequencing, molecular biology, immunology, cell biology, stem cell research, and other applications.

Today's announcement is the third from NanoInk in the past year covering distribution deals in Asia. In the fall it signed on E-Hong to distribute its products in Taiwan, and last May it announced a non-exclusive agreement with the Research Institute of Biomolecule Metrology for distribution of its products in Japan.

The Scan

Self-Reported Hearing Loss in Older Adults Begins Very Early in Life, Study Says

A JAMA Otolaryngology — Head & Neck Surgery study says polygenic risk scores associated with hearing loss in older adults is also associated with hearing decline in younger groups.

Genome-Wide Analysis Sheds Light on Genetics of ADHD

A genome-wide association study meta-analysis of attention-deficit hyperactivity disorder appearing in Nature Genetics links 76 genes to risk of having the disorder.

MicroRNA Cotargeting Linked to Lupus

A mouse-based study appearing in BMC Biology implicates two microRNAs with overlapping target sites in lupus.

Enzyme Involved in Lipid Metabolism Linked to Mutational Signatures

In Nature Genetics, a Wellcome Sanger Institute-led team found that APOBEC1 may contribute to the development of the SBS2 and SBS13 mutational signatures in the small intestine.